Curis, Inc. (“Curis”) is hereby furnishing information regarding its multi-targeted inhibitor cancer programs that it intends to provide to investors and other third parties from time to time as part of its investor relations and business development activities, including at the BioSquare 2007 conference being held in Lyon, France from March 12-14, 2007. A copy of such information is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.